NCT05862259

A Real-world Study of the Efficacy and Safety of ICIs as First-line Therapy for Advanced Malignancies

A Multicenter, Multiomics, Non-interventional, Real-world Study of the Efficacy and Safety of Immune Checkpoint Inhibitors as First-line Therapy for Advanced Malignancies

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 120 (estimated)
• Sponsor: Xinqiao Hospital of Chongqing · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

In this study, we collected the data of immunohistochemistry, gene detection, image, OS, PFS, Orr, and so on. Secondly, the database of immunotherapy for malignant tumor was established, and the predictive model was constructed to verify and establish the rationality and validity of the biomarkers and predictive system of immunotherapy

Conditions

• Malignant Tumor
• Immunotherapy
• Artificial Intelligence

Timeline

• Start date: 2023-08-10
• Primary completion: 2025-08-10
• Completion: 2025-12-31
• First posted: 2023-05-17
• Last updated: 2025-07-14

Locations

1 site across 1 country: China